# Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC

> **NCT04372732** · — · UNKNOWN · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 200 (estimated)

## Conditions studied

- Lung Cancer
- Immunotherapy

## Interventions

- **DIAGNOSTIC_TEST:** Serum tumor autoantibody detection

## Key facts

- **NCT ID:** NCT04372732
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2022-06
- **Final completion:** 2022-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04372732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04372732, "Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04372732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*